Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases)

Adv Pediatr Infect Dis. 1997;13:1-47.
No abstract available

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antiviral Agents / administration & dosage
  • Bronchiolitis, Viral / pathology
  • Bronchiolitis, Viral / therapy
  • Bronchodilator Agents / administration & dosage
  • Bronchopulmonary Dysplasia / complications
  • Bronchopulmonary Dysplasia / therapy
  • Cost-Benefit Analysis
  • Disease Models, Animal
  • Heart Defects, Congenital / complications
  • Humans
  • Immunization, Passive / economics
  • Immunization, Passive / methods
  • Immunocompromised Host
  • Infant
  • Infant, Newborn
  • Pneumonia, Viral / pathology
  • Pneumonia, Viral / therapy
  • Respiratory Syncytial Virus Infections / epidemiology
  • Respiratory Syncytial Virus Infections / pathology
  • Respiratory Syncytial Virus Infections / prevention & control
  • Respiratory Syncytial Virus Infections / therapy*
  • Respiratory Syncytial Virus, Human*
  • Ribavirin / administration & dosage
  • Vaccination / economics
  • Vaccination / methods

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antiviral Agents
  • Bronchodilator Agents
  • Ribavirin